AbbVie is investing $380 million to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie’s next-generation neuroscience and obesity medications.

Construction will begin in spring 2026, with both new facilities expected to be fully operational in 2029. To support these new facilities, AbbVie plans to hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians.

“This milestone demonstrates further progress against our $100 billion commitment to U.S. R&D and capital investments over the next decade,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients.”

Over the past six months, AbbVie has announced plans to significantly expand its API manufacturing capabilities and capacity in the U.S. In September 2025, AbbVie broke ground on the first phase of this investment, a new chemical synthesis facility that will enable the return of API production for select neuroscience, immunology and oncology products from Europe and Asia to the U.S.

In addition to its planned investments in Illinois, AbbVie says it is currently in discussions with multiple U.S. states about potential manufacturing investments and anticipates announcing additional investments in 2026.